US Stock MarketDetailed Quotes
EXAS Exact Sciences
- 44.840
- -0.490-1.08%
Close Jul 11 16:00 ET
- 44.200
- -0.640-1.43%
Post 19:04 ET
8.27BMarket Cap-34229P/E (TTM)
46.900High43.480Low4.83MVolume46.310Open45.330Pre Close218.05MTurnover2.64%Turnover RatioLossP/E (Static)184.53MShares100.77052wk High2.64P/B8.21BFloat Cap40.62452wk Low--Dividend TTM183.19MShs Float159.540Historical High--Div YieldTTM7.55%Amplitude0.220Historical Low45.113Avg Price1Lot Size
Exact Sciences Stock Forum
Sign in to post a comment
$Exact Sciences(EXAS.US$ guys relax sooner or later this will grow just not so soon
1
1
$Exact Sciences(EXAS.US$ whats happening? why it keeps dropping?
$Exact Sciences(EXAS.US$ Good opportunity to buy after correction, "not today" I shall buy in next week once volatility minimized. Good AI stoks but you can see good return not before 2025. I am bullish on it and it will remain my best pick for next 3-5 years invetment tenure.
2
Exact Sciences' progress has failed to meet high market expectations, yet its consistent revenue growth suggests it may be worth further investigation. The company's performance has underperformed the broader market, which gained around 31%.
2
The company's strained balance sheet and lack of EBIT level profitability heighten risk. Its debt management and growth rate are key concerns, with faster growth expected from unprofitable firms.
Exact Sciences' low P/S ratio is due to its poor revenue outlook. Investors foresee limited growth, thus are only willing to pay less for the stock, making a strong share price rise unlikely.
Exact Sciences' growth rate is somewhat slow, showing a 20% rise in revenue while lacking profitability at an EBIT level. Considerable liabilities and negative EBIT results make its financial status seem precarious and risky.
Impressive annual returns suggest the company's improved performance. Its focus on revenue growth proves strategic, although further profitability analysis is wise given the substantial share appreciation.
Gapping up
$Coinbase(COIN.US$+2.38% (The crypto exchange stock climbed in premarket trading, seemingly aided by the surge in bitcoin's 7.8% climb. Coinbase has faced a multiple headwinds recently, from an ongoing spat with the U.S. Securities and Exchange Commission to BlackRock's launch of its own bitcoin exchange-traded fund.)
$MicroStrategy(MSTR.US$+2.58% (Shares have climbed more than 121% so far in 2023 and 8.7% over the past...
$Coinbase(COIN.US$+2.38% (The crypto exchange stock climbed in premarket trading, seemingly aided by the surge in bitcoin's 7.8% climb. Coinbase has faced a multiple headwinds recently, from an ongoing spat with the U.S. Securities and Exchange Commission to BlackRock's launch of its own bitcoin exchange-traded fund.)
$MicroStrategy(MSTR.US$+2.58% (Shares have climbed more than 121% so far in 2023 and 8.7% over the past...
18
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Baboompiak : yup holding onto 100 shares at 57.5